Was the GlaxoSmithKline FCPA resolution a missed opportunity?

Tom Fox questions whether U.S. regulators missed a chance to illustrate how they would give credit for anti-corruption prosecutions done by other governments in the case of GlaxoSmithKline’s China subsidiary’s recent FCPA resolution.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.